The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, and X4 are each independently CR6 or N； provided that no more than two of X1, X2, X3, or X4 are N； Q2 is N or NR5a； one of Q1 and Q3 is CR5, and the other is N or NR5a； and the dashed circle denotes optional bonds forming an aromatic ring； Y1 is O or NR3； Y2 is -CO-, -SO2-, or -S(O(NH)-； Y3 is O or NR4a； provided that (1) Y1 and Y3 are not both O, and (2) when Y2 is C(O), Y1 is not O； L is a covalent bond or C1-4 alkylene substituted with 0 to 4 R7； R1 is (-CH2)aR9； a is an integer of 0 or 1； R2 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxy, alkoxyalkyl, haloalkoxyalkyl, or haloalkoxy； n is an integer of 0, 1, or 2； R3 and R4a are independently hydrogen, C1-6 alkyl, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy； R4 is C1-10 alkyl, C1-10 haloalkyi, C1-10 deuterated alkyl, C1-10 alkenyl, C3-8 cycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, -(Ci-6 alkylene)-(C3-8 cycloalkyl), -(C1-6 alkylene)-(6 to 10-membered aryl), -(C1-6 alkylene)-(3 to 8-membered heterocyclyl), or -(C1-6 alkylene)-(5 to 6-membered heteroaryl)； wherein each of the alkyl, alkylene, alkenyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl, by itself or as part of other moiety, is independently substituted with 0 to 3 R； or alternatively, R3 and R4, taken together with the N and 0 atoms which they are attached, form a 4 to 9-membered heterocyclic ring moiety which is substituted with 0 to 3 R8； or alternatively, (R3 and R5a) or (R3 and R5), taken together with the atoms to which they are attached to, form a 5 to 8-membered heterocyclic ring moiety which is substituted with 0 to 3 R8； R5a is hydrogen, C1-6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloa
